Sunday 18 October 2026
Export KYTX’s income statement to Excel — free account
Kyverna Therapeutics, Inc.
KYTX Healthcare Biotechnology
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million. In the quarter to June 2026, EPS grew 35.1%, free cash flow fell 27.1% and total debt rose 95,603.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.67
0.30
−5.03%
Follow KYTX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 3.54 | 1.78 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 35.06 | 13.67 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 84 | 96 | 112 | 130 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.08 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 7 | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 100.00 | — | — | — | |||||
| EBT | — | — | — | — | — | — | (29) | (60) | (127) | (161) | |||||
| EBT margin, % | — | — | — | — | — | — | (411.29) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (29) | (60) | (127) | (161) | |||||
| Depreciation | — | — | — | — | — | — | 1 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 15.42 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (63.43) | (89.61) | (3.33) | (3.64) | |||||
| Cash flow | — | — | — | — | — | — | (79.28) | (77.76) | (2.98) | (3.47) | |||||
| Capex | — | — | — | — | — | — | (1.69) | (0.92) | (0.06) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (80.97) | (78.68) | (3.04) | (3.47) | |||||
| Book value | — | — | — | — | — | — | (162.45) | (194.95) | 6.95 | 5.25 | |||||
| Shares, m | — | — | — | — | — | — | 0 | 1 | 38 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | 0.69 | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (36) | (52) | (114) | (154) | ||||
| Capex | — | — | — | — | — | — | (1) | (1) | (2) | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (37) | (53) | (116) | (154) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 41 | 257 | 246 | ||||
| Total debt | — | — | — | — | — | — | 1 | 1 | 0 | 25 | |||||
| Net debt | — | — | — | — | — | — | (50) | (57) | (286) | (255) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (74) | (131) | 267 | 232 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (84.95) | (67.12) | (53.91) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 58.78 | (188.59) | (64.67) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022
Charts ten years each
Kyverna Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RZLT Rezolute, Inc. | $377.2M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDIT Editas Medicine, Inc. | $374.7M | — (loss-making) | — (loss-making) | +232.31% (above 0%: growing) | n/m | +40.72% (above 0%: growing) | 100.00% | (156.05%) | Compare |
| GALT Galectin Therapeutics Inc. | $374.2M | — (loss-making) | — | — | n/m | +63.06% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KYTX Kyverna Therapeutics, Inc. | $369.2M | — (loss-making) | — (loss-making) | — | n/m | −27.06% (below 0%: shrinking) | — | 0.00% | |
| AVIR Atea Pharmaceuticals, Inc. | $363.3M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| FENC Adherex Technologies Inc. | $362.9M | — (loss-making) | 31.4× | +85.18% (above 0%: growing) | n/m | +101.36% (above 0%: growing) | 95.97% | 9.72% | Compare |
| TTRX Turn Therapeutics Inc. | $345.3M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $345.0M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| CCCC C4 Therapeutics, Inc. | $342.0M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | +86.84% (above 0%: growing) | 100.00% | (397.88%) | Compare |
| Median of peers | $363.1M | — | — | +85.18% | — | +51.89% | 71.59% | 0.00% |
Kyverna Therapeutics, Inc. (KYTX) key facts
- Kyverna Therapeutics, Inc. (KYTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million.
- As of October 16, 2026, KYTX traded at $5.67, a market capitalization of $369.2 million.
- Return on equity was −64.7% and debt-to-equity 0.15.